Atypical antipsychotic augmentation for treatment-resistant depression: A systematic review and network meta-analysis

International Journal of Neuropsychopharmacology

Volumn 18, Issue 11, 2015, Pages

  Zhou, Xinyu ^a   Keitner, Gabor I ^b   Qin, Bin ^a   Ravindran, Arun V ^c   Bauer, Michael ^d   Del Giovane, Cinzia ^e   Zhao, Jingping ^f   Liu, Yiyun ^a   Fang, Yiru ^g   Zhang, Yuqing ^a   Xie, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Atypical antipsychotics; Network meta analysis; Systematic review; Treatment resistant depression

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; NEUROLEPTIC AGENT;

COMPARATIVE EFFECTIVENESS; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESISTANT DEPRESSION; ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84983316893     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv060     Document Type: Review

References (67)

1. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20:177-184.
2. Attari A, Moghaddam Y, Hasanzadeh A, Soltani M, Mahmoodi M (2006) Comparison of effcacy of fuoxetine with nortriptyl-ine in treatment of major depression in children and adolescents: a double-blind study. J Res Med Sci 11:24-30.
3. Barnes SA, Lindborg SR, Seaman JW (2006) Multiple imputation techniques in small sample clinical trials. Stat Med 25:233-45.
4. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540-549.
5. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive D (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334-385.
6. Bech P (2005) Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 19:313-324.
7. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C (2006) An international, multicenter, placebo-controlled trial of par-oxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 16:59-75.
8. Berlim MT, Turecki G (2007) Defnition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 52:46-54.
9. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A (2007) The effcacy and safety of ari-piprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843-853.
10. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197-206.
11. Blier P, Szabo ST (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 66(Supp 8):30-40.
12. Brooks SP, Gelman A (1998) General Methods for Monitoring Convergence of Iterative Simulations. J Comput Graph Stat 7:434-455.
13. Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F (2009) Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLOS One 4:e4824.
14. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative effcacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
15. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (2011) Comparative effcacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:1306-1315.
16. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G (2006) A randomized, double-blind comparison of olanzap-ine/fuoxetine combination, olanzapine, fuoxetine, and ven-lafaxine in treatment-resistant depression. Depress Anxiety 23:364-372.
17. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM (2002) The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63:963-971.
18. Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grim-shaw J (2008) Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. Can Med Assoc J 178:1293-1301.
19. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neu-ropsychop 13:917-932.
20. Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
21. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M (2012) A double-blind, placebo-controlled study of aripiprazole adjunctive to anti-depressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81:87-97.
22. Finley PR (2009) Mood disorders: major depressive disorders. In: Applied therapeutics: the clinical use of drugs, 9th ed., (Koda-Kimble MA, Young LY, Alldredge BK, Corelli RL, Guglielmo BJ, Kradjan WA, Williams BR, ds.), pp 1-32. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins.
23. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM (1991) Conceptualization and rationale for consensus defnitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855.
24. Guo WB, Liu F, Xue ZM, Gao K, Wu RR, Ma CQ, Liu ZN, Xiao CQ, Chen HF, Zhao JP (2012a) Altered white matter integrity in young adults with frst-episode, treatment-naive, and treatment-responsive depression. Neurosci Lett 522:139-144.
25. Guo WB, Liu F, Chen JD, Gao K, Xue ZM, Xu XJ, Wu RR, Tan CL, Sun XL, Liu ZN, Chen HF, Zhao JP (2012b) Abnormal neural activity of brain regions in treatment-resistant and treatment-sensitive major depressive disorder: a resting-state fMRI study. J Psychiatr Res 46:1366-1373.
26. Hamilton M (1960) A rating scale for depression. J Neurol Neuro-surg Psychiatry 23:56-62.
27. Healy D (2000) The assessment of outcomes in depression: measures of social functioning. Rev Contemp Pharmacother 11:295-301.
28. Hicks P, Hicks XP, Meyer H, Shisslak C (2010) How best to manage treatment-resistant depression? J Fam Pract 59:490-497.
29. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. Retrieved March 10, 2014. http://handbook.cochrane.org.
30. Iovieno N, Papakostas GI (2012) Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry 73:1300-6.
31. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T, Group AS (2013) Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 151:899-905.
32. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with diffcult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43:205-214.
33. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 117(Supp 1):S1-2.
34. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey R (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105.
35. Khullar A, Chokka P, Fullerton D, McKenna S, Blackamn A (2006) A double-blind, randomized, placebo-controlled study of que-tiapine as augmentation therapy to SSRI/SNRI agents in the treatment of non-psychotic unipolar depression with residual symptoms. Paper presented at: New Research Abstracts of American Psychiatric Association 2006 Annual Meeting; 20 May 2006; Toronto, Canada.
36. Kirsch I, Moncrieff J (2007) Clinical trials and the response rate illusion. Contemp Clin Trials 28:348-351.
37. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (2010) Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 12:CD008121.
38. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative effcacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951-962.
39. Liu Y, Zhou X, Qin B, Del Giovane C, Zhang Y, Xie P (2014) Effcacy, quality of life, and acceptability outcomes of atypical antip-sychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis. Syst Rev 3:133.
40. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105-3124.
41. Lu G, Ades A (2006) Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 101:447-459
42. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM (2007) Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 147:593-602.
43. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM (2008) The eff-cacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156-165.
44. Mattingly G, Ilivicky H, Canale J, Anderson R (2006) Quetiapine combination for treatment-resistant depression. Paper presented at: New Research Abstracts of American Psychiatric Association 2006 Annual Meeting; May 20, 2006; Toronto, Canada.
45. McIntyre A, Gendron A, McIntyre A (2007) Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 24:487-494.
46. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-anal-yses: the PRISMA statement. The BMJ 339:b2535.
47. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
48. Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psych 166:980-991.
49. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nieren-berg AA, Fava M (2004) Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 26:13-17.
50. Papakostas GI, Shelton RC, Smith J, Fava M (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826-831.
51. Papakostas GI, Østergaard SD, Iovieno N (2015) The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 76:456-66.
52. Psychopharmacology Institute (2013) Second generation antip-sychotics (atypicals). Retrieved March 27, 2015.http://psy-chopharmacologyinstitute.com/antipsychotics/.
53. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X (2008) Effcacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69:1228-1336.
54. Salanti G, Higgins JP, Ades AE, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17:279-301.
55. Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163-171.
56. Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. Int Clin Psychopharmacol 11(Supp 3):89-95.
57. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001) A novel augmentation strategy for treating resistant major depression. Am J Psych 158:131-134.
58. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD (2005) Olanzapine/fuox-etine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66:1289-1297.
59. Shelton RC, Osuntokun O, Heinloth AN, Corya SA (2010) Therapeutic options for treatment-resistant depression. CNS Drugs 24:131-161.
60. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLOS Med 10:e1001403.
61. Taylor D (2000) Low dose typical antipsychotics-a brief evaluation. Psychiatric Bulletin 24:465-468.
62. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dube S (2007) A randomized, double-blind comparison of olanzapine/fuoxetine combination, olanzap-ine, and fuoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 68:224-236.
63. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, Team SDS (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psych 163:28-40.
64. Ucok A, Gaebel W (2008) Side effects of atypical antipsychotics: a brief overview. World Psychiatry 7:58-62.
65. Vieta E, Colom F (2011) Therapeutic options in treatment-resistant depression. Ann Med 43:512-530.
66. Ware JE, Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483.
67. Zhou X, Ravindran A, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P (2014) Comparative effcacy, acceptability and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 76:e487-498.